| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||
Net loss | ||||||
-36,698 | -38,980 | -23,233 | ||||
Adjustments to reconcile net loss to cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
810 | 760 | - | ||||
Deferred rent | ||||||
- | -345 | - | ||||
Common stock to be issued pursuant to license agreements | ||||||
- | - | 5,036 | ||||
Depreciation | ||||||
- | - | 419 | ||||
Deferred rent | ||||||
- | - | 109 | ||||
Stock-based compensation | ||||||
6,520 | 7,173 | 2,775 | ||||
Operating lease right of use amortization | ||||||
4,354 | - | - | ||||
Loss on disposal of fixed asset | ||||||
-54 | -3 | -10 | ||||
Non-cash investment income | ||||||
72 | -76 | - | ||||
Changes in operating assets and liabilities: | ||||||
Account receivable | ||||||
754 | - | - | ||||
Prepaid expenses and other current assets | ||||||
-487 | 701 | 1,116 | ||||
Other assets | ||||||
-123 | - | - | ||||
Operating lease liability | ||||||
-4,277 | - | - | ||||
Deposits | ||||||
-1,559 | -787 | - | ||||
Deposits | ||||||
- | - | -58 | ||||
Accounts payable | ||||||
-1,152 | 376 | 921 | ||||
Accrued expenses | ||||||
439 | 636 | 712 | ||||
Research and development contract liability | ||||||
928 | 4,686 | 2,500 | ||||
Net cash used in operating activities | ||||||
-30,796 | -26,410 | -12,141 | ||||
Cash flows from investing activities | ||||||
Acquisition of trademark | ||||||
- | - | 175 | ||||
Purchases of property and equipment | ||||||
46 | 1,854 | 1,029 | ||||
Redemption of short term investments | ||||||
-18,500 | -21,000 | - | ||||
Purchase of short term investments | ||||||
15,134 | 39,500 | - | ||||
Increase in certificate of deposit | ||||||
- | - | 0 | ||||
Cash received from sale of fixed asset | ||||||
127 | - | - | ||||
Net cash (used in) provided by investing activities | ||||||
3,446 | -20,354 | -1,204 | ||||
Cash flows from financing activities | ||||||
Proceeds from private placements of common stock | ||||||
48,998 | 4,169 | - | ||||
Restricted stock repurchase at vesting to cover taxes | ||||||
91 | - | - | ||||
Proceeds from sale of placement agent and underwriters warrants | ||||||
- | - | 1 | ||||
Proceeds from the initial public offering of common stock | ||||||
- | - | 66,155 | ||||
Proceeds from exercise of stock options | ||||||
1,881 | 12 | 8 | ||||
Cash payments made for costs incurred in connection with sale of common stock | ||||||
- | - | 4,159 | ||||
Net cash provided by financing activities | ||||||
50,789 | 4,181 | 62,004 | ||||
Net increase/(decrease) in cash, cash equivalents, and restricted cash | ||||||
23,439 | -42,583 | 48,657 | ||||
Supplemental disclosures of cash flow information: | ||||||
Income taxes | ||||||
412 | 825 | - | ||||
Fair value of warrants issued in connection with issuance of common stock | ||||||
- | - | 4,086 | ||||
Public offering costs included in accounts payable or accrued expenses | ||||||
- | - | 150 | ||||
Purchases of property and equipment in accounts payable or accrued expenses | ||||||
- | - | 67 | ||||
Restricted Stock | ||||||
Issuance of restricted stock awards | ||||||
12 | - | - | ||||